HSA/FSA Accounts & GLP-1 Affordability Programs

💳

HSA & FSA Accounts for GLP-1 Medications

Health savings accounts and flexible spending arrangements offer pre-tax dollars that can offset GLP-1 costs — but eligibility rules hinge critically on your diagnosis, not just the drug itself.

HSA and FSA cards with prescription medication representing GLP-1 affordability tools for health savings accounts — HSA and FSA funds can be used for GLP-1 prescriptions when the medication is prescribed for a qualifying medical condition — but the specific diagnosis matters greatly.

Critical HSA/FSA Rule: Diagnosis Determines Eligibility

GLP-1 medications are HSA/FSA-eligible only when prescribed for a qualifying medical condition — specifically type 2 diabetes or, since 2023, cardiovascular risk reduction. GLP-1s prescribed solely for weight loss or obesity (without a co-qualifying diagnosis) are NOT currently eligible for HSA or FSA reimbursement under IRS rules. Consult your tax advisor and confirm with your HSA/FSA administrator before submitting a claim, as policies can vary by plan administrator. Misuse of HSA funds for ineligible expenses results in income tax plus a 20% penalty.

Health Savings Accounts (HSA) — Rules & Strategy

HSAs are available only to individuals enrolled in a High-Deductible Health Plan (HDHP). For 2024, the HSA contribution limit is $4,150 for individuals and $8,300 for families, with a $1,000 catch-up contribution allowed for those 55 and older. The triple tax advantage — pre-tax contributions, tax-free growth, and tax-free withdrawals for qualified medical expenses — makes HSAs one of the most powerful financial tools for managing chronic medication costs like GLP-1 therapy when prescribed for diabetes. Many HSA custodians (Fidelity, HealthEquity, Optum Bank) allow you to invest HSA funds in mutual funds or ETFs once your balance exceeds a threshold, turning the account into a long-term medical investment vehicle.

HSA Strategy

Flexible Spending Accounts (FSA) — Use-It-or-Lose-It Planning

FSAs allow pre-tax contributions up to $3,200 (2024 limit) for healthcare expenses and are not tied to HDHP enrollment — making them accessible to more employees. The key FSA caveat: funds must be used within the plan year (with some plans offering a $640 grace period carryover or a 2.5-month extension). For GLP-1 users with a qualifying diabetes or cardiovascular diagnosis, FSA funds can cover copays, deductibles, and out-of-pocket prescription costs. Strategic FSA planning — timing enrollment to align with the start of GLP-1 therapy — can effectively front-load pre-tax dollars to offset first-year costs. Check with your FSA administrator (WageWorks, Optum, Benefitfocus) about their specific GLP-1 documentation requirements.

FSA Planning

Health Reimbursement Arrangements (HRA)

HRAs are employer-funded accounts that reimburse employees for qualified medical expenses, including prescriptions. Individual Coverage HRAs (ICHRAs) — available since 2020 — allow employers of any size to reimburse employees for individual market health insurance premiums and medical expenses, with no contribution limits. For GLP-1 users at companies that offer HRAs instead of or alongside traditional insurance, submitting GLP-1 prescription receipts for reimbursement (when prescribed for an eligible diagnosis) can recover hundreds of dollars monthly. Qualified Small Employer HRAs (QSEHRAs) cap at $6,150 per individual in 2024. HR administrators at companies in cities like Nashville, Phoenix, and San Diego are increasingly being asked about HRA coverage for GLP-1s.

HRA Programs

Maximizing Pre-Tax Accounts for Long-Term GLP-1 Therapy

For patients on GLP-1 therapy long-term (often years for chronic weight management or cardiovascular protection), maximizing HSA contributions annually and investing the balance creates a compounding medical fund. At a 7% average annual return, a maxed HSA over 10 years accumulates over $57,000 in tax-free medical spending power — enough to cover substantial GLP-1 costs even without insurance. Financial planners who specialize in healthcare — including those affiliated with NAPFA in cities like Boston, Chicago, and San Francisco — increasingly build GLP-1 medication costs into long-term financial plans for clients managing obesity-related chronic conditions.

Long-Term Planning

Medicare and Medicaid cards representing government insurance coverage options for GLP-1 medications for diabetes and obesity

Dependent Care vs. Medical FSA — Know the Difference

Many employees confuse Dependent Care FSAs (for childcare/elder care costs) with Healthcare FSAs (for medical expenses). Only Healthcare FSAs can be used for GLP-1 prescription costs. You can contribute to both types simultaneously if your employer offers both, but they are completely separate accounts with different eligible expense categories.

Healthcare FSA: covers prescriptions, copays, deductibles, medical devices — including GLP-1 drugs for eligible diagnoses
Dependent Care FSA: covers daycare, after-school programs, summer camps — never prescription drugs
Limited-Purpose FSA: covers only dental and vision — cannot be used for GLP-1 medications

🏛️

Medicare, Medicaid & State-Level GLP-1 Coverage Programs

Government insurance programs have complex and evolving GLP-1 coverage rules — and state-level expansions are creating new access pathways for millions of Americans who previously had no options.

Medicare Part D & the GLP-1 Coverage Gap

As of 2024, Medicare Part D covers semaglutide (Ozempic) and tirzepatide (Mounjaro) when prescribed for type 2 diabetes, but explicitly excludes coverage for weight loss alone — meaning Wegovy and Zepbound (the obesity-indicated formulations) are not covered under standard Medicare. The Inflation Reduction Act (IRA) of 2022 capped Medicare Part D out-of-pocket drug costs at $2,000/year starting in 2025, which helps diabetes patients on GLP-1 therapy. Advocates from the Obesity Action Coalition have been lobbying for the Treat and Reduce Obesity Act (TROA), which would expand Medicare Part D to cover anti-obesity medications — a legislative change that could benefit millions of seniors in states like Florida, Arizona, and Pennsylvania with large Medicare populations.

Medicare Part D

Medicaid GLP-1 Coverage by State

Medicaid coverage for GLP-1 medications varies dramatically by state. As of 2025, approximately 34 states cover GLP-1 medications through Medicaid for type 2 diabetes management. Coverage for obesity-specific GLP-1 indications is far more limited — only a handful of states including California, New York, and Connecticut have proactively added anti-obesity medication coverage to their Medicaid formularies. States like Texas, Florida, and Georgia have among the most restrictive Medicaid GLP-1 formularies despite having high rates of obesity and type 2 diabetes. Patients can appeal Medicaid formulary exclusions with physician support documentation, and some states have expanded access through managed care organization (MCO) supplemental benefits.

Medicaid Coverage

State Expansion Programs — California, New York, Illinois & Massachusetts

Several states have led the way in expanding GLP-1 access beyond federal minimums. California's Medi-Cal program added Wegovy and Zepbound to its formulary for qualifying members with BMI ≥30 in late 2024, reaching approximately 14 million low-income Californians. New York's Medicaid program covers anti-obesity medications with prior authorization for members with obesity-related comorbidities. Illinois implemented a GLP-1 access expansion through its Medicaid managed care plans serving Chicago and Cook County. Massachusetts MassHealth covers semaglutide for qualifying members, with a structured prior authorization pathway developed in partnership with Harvard-affiliated obesity medicine specialists. Patients in these states should contact their Medicaid managed care plan directly to confirm current formulary status.

State Programs

Patient Advocacy & Appeals Assistance Organizations

Several nonprofit organizations provide free assistance to patients appealing GLP-1 coverage denials or navigating complex affordability programs. The Obesity Action Coalition (OAC) offers a free insurance appeals toolkit and connects patients with trained patient advocates. The Patient Advocate Foundation provides case management services for patients facing coverage denials, including GLP-1 medications, across all 50 states. NeedyMeds.org maintains a comprehensive database of patient assistance programs (PAPs) from pharmaceutical manufacturers, including the Novo Nordisk Patient Assistance Program and Lilly Cares Foundation. Benefits counselors at federally qualified health centers (FQHCs) — available in underserved areas of states including Mississippi, West Virginia, and New Mexico — can help patients identify and enroll in all available programs simultaneously.

Advocacy & Appeals

▶ Using HSA and FSA for Prescription Medications Including GLP-1

GLP-1 Government Coverage Across the United States

Access to government-funded GLP-1 coverage is deeply uneven across the United States, reflecting broader healthcare inequities. The Northeast — including Massachusetts, Connecticut, New York, and New Jersey — generally offers the most comprehensive Medicaid GLP-1 access. The West Coast (California, Oregon, Washington) has seen rapid expansion driven by state legislative action. The Mountain West and Great Plains states (Idaho, Wyoming, North Dakota, South Dakota) have the most restrictive formularies with limited appeal pathways. In the South — including Alabama, Mississippi, Louisiana, and Arkansas, which have some of the nation's highest obesity rates — Medicaid GLP-1 access for weight management remains severely restricted, creating a stark equity gap. Medicare patients nationwide are affected by the current federal exclusion of anti-obesity medications, which advocacy groups are actively working to reverse through federal legislation. Veterans Affairs (VA) hospitals in cities like Houston, Phoenix, Atlanta, and Seattle have their own GLP-1 formularies and tend to cover both diabetes and obesity indications for eligible veterans.

HSA & FSA Accounts for GLP-1 Medications — Plus Medicare, Medicaid & State Programs